Literature DB >> 29472057

Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab.

Amel Boudjemaa1, Gaelle Rousseau-Bussac1, Isabelle Monnet2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472057     DOI： 10.1016/j.jtho.2017.10.023

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

Review 1.  Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review.

Authors:  Pedro Iglesias; Juan Cristóbal Sánchez; Juan José Díez
Journal:  Pituitary       Date:  2021-03-24       Impact factor: 4.107

2.  Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.

Authors:  Marcus A Couey; R Bryan Bell; Ashish A Patel; Meghan C Romba; Marka R Crittenden; Brendan D Curti; Walter J Urba; Rom S Leidner
Journal:  J Immunother Cancer       Date:  2019-07-03       Impact factor: 13.751

3.  Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.

Authors:  Satoshi Yamagata; Kazunori Kageyama; Shinobu Takayasu; Yuko Asari; Koshi Makita; Ken Terui; Makoto Daimon
Journal:  Intern Med       Date:  2019-08-28       Impact factor: 1.271

4.  Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report.

Authors:  Sho Tanaka; Masanori Abe; Masaru Kushimoto; Tsukasa Nishizawa; Masahiro Takubo; Kazutaka Mitsuke; Jin Ikeda; Midori Fujishiro; Katsuhiko Ogawa; Ichiro Tsujino; Yutaka Suzuki
Journal:  Clin Diabetes Endocrinol       Date:  2020-01-06

5.  Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study.

Authors:  Kai Cui; Ziqi Wang; Qianqian Zhang; Xiaoju Zhang
Journal:  Ann Transl Med       Date:  2022-03

6.  Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review.

Authors:  Dandan Geng; Yingnan Wang; Xin Zhang; Chenguang Zhao; Yao Fan; Chang Liu; Jinmei Wei; Bingjie Huo; Yang Zhao; Fengbin Zhang; Ruixing Zhang
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

7.  Exploring a New Entity of Single-Agent Pembrolizumab-Associated Hypophysitis.

Authors:  Eric Balti; Sarah Verhaeghe; Vibeke Kruse; Stijn Roels; Peter Coremans
Journal:  Cureus       Date:  2022-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.